Phase 1 Crossover Study to Assess the Effects of SQ109 on QTc Interval in Healthy Subjects

Trial Profile

Phase 1 Crossover Study to Assess the Effects of SQ109 on QTc Interval in Healthy Subjects

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 14 May 2014

At a glance

  • Drugs SQ 109 (Primary) ; Moxifloxacin
  • Indications Crohn's disease; Duodenal ulcer; Helicobacter infections; Mycobacterial infections; Mycoses; Tuberculosis
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Mar 2014 Trial status changed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 13 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 28 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top